Prolia is a monoclonal antibody that binds to a specific protein on osteoclasts and decreases their activity. Osteoclasts are responsible for dissolving and breaking down old or damaged bone cells. By ...

Prolia (denosumab) is a medication for osteoporosis. A healthcare professional administers Prolia via injection under the skin every 6 months. Medicare covers Prolia for beneficiaries. Since a ...

Denosumab (Prolia) is a leading treatment for osteoporosis, but the rapid bone loss that can occur after discontinuing the RANK ligand inhibitor can be challenging to navigate. "I don't think we have ...

(Reuters) - Amgen Inc, the world's largest biotechnology company, said U.S. health regulators approved its Prolia injection for a new use as a treatment to increase bone mass in men with osteoporosis ...

The Food and Drug Administration has approved Fresenius Kabi's Biologics License Application for the denosumab biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht). These denosumab ...

Please provide your email address to receive an email when new articles are posted on . Compared with oral bisphosphonate use, denosumab use was associated with a 45% lower risk for fractures among ...